Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects [0.03%]
大规模分析证明CYP2C19基因型对特定SSRI副作用的影响
Chris Eijsbouts,Yunxuan Jiang,James R Ashenhurst et al.
Chris Eijsbouts et al.
We evaluated the effect of CYP2C19 genotype on SSRI response in 114,627 research participants. We graded metabolizer status (0 for ultrarapid metabolizers to 4 for poor metabolizers), and regressed drug response outcomes on these grades. Am...
Effects of CYP3A4, CYP3A5, and ABCB1 genetic variants on tacrolimus metabolism during the early period after kidney transplantation [0.03%]
CYP3A4、CYP3A5和ABCB1基因多态性对肾移植术后早期他克莫司代谢的影响
Nahathai Dukaew,Kajohnsak Noppakun,Mingkwan Na Takuathung et al.
Nahathai Dukaew et al.
Tacrolimus (TAC) exhibits substantial interindividual pharmacokinetic variability, complicating early dose optimization after kidney transplantation. This study evaluated the effects of CYP3A5 rs776746 (6986A > G), CYP3A4 rs4646437 (G > A),...
Understanding public perspectives on direct-to-consumer pharmacogenomic testing in the UK: a qualitative study [0.03%]
英国消费者对直接面向消费者的药物基因组学检测的看法：一项定性研究
Amy Mathieson,Lisa Brunton,Stephanie Gillibrand et al.
Amy Mathieson et al.
Direct-to-consumer (DTC) pharmacogenomic (PGx) testing is expanding rapidly in the UK, yet no dedicated regulatory framework currently governs these services. Although a 2021 parliamentary inquiry recommended stronger safeguards and clearer...
Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variants [0.03%]
与免疫治疗相关的尿路上皮癌毒性：肿瘤遗传风险变异体
J M Rodríguez-Piñas,A Romero-Lorca,A Novillo et al.
J M Rodríguez-Piñas et al.
The treatment of urothelial cancer (UC) has been revolutionized by the introduction of immune checkpoint inhibitors (ICIs). However, while ICIs have achieved better therapeutic results than traditional chemotherapeutic agents, immune-relate...
Beyond the 'Pregnancy Black Box': a global roadmap for artificial intelligence-driven pharmacogenomics in maternal-neonatal health [0.03%]
走出孕期研究的“黑箱”：促进人工智能驱动的药物基因组学在孕产妇新生儿健康领域的发展路线图
Mohamed A Ismail
Mohamed A Ismail
Maternal and neonatal health (MNH) urgently requires precision medicine interventions, as morbidity, mortality, and health disparities hinder the achievement of Sustainable Development Goal 3. Clinical implementation of artificial intellige...
The association of ABCB1, CYP2C19 and CYP2C9 combined activity with clopidogrel resistance in patients with recurrent ischemic stroke [0.03%]
ABCB1、CYP2C19和CYP2C9联合基因多态性与氯吡格雷抵抗的复发性缺血性卒中患者的关联分析
Birgit Deiman,Mike Hermans,Maarten de Rijk et al.
Birgit Deiman et al.
Clopidogrel therapy is recommended to prevent recurrent ischemic stroke. However, clopidogrel resistance exists. This study examines which enzymes are involved in clopidogrel resistance. The study group includes 402 neurology patients who h...
Development and validation of an open data model for pharmacogenetics to enable semantic interoperability in clinical practice [0.03%]
用于药物基因组学的开放数据模型的发展与验证以实现临床实践中的语义互操作性
Videha Sharma,John H McDermott,Jessica Keen et al.
Videha Sharma et al.
Pharmacogenetics uses genetic testing to improve the safety and effectiveness of prescribed medicines, yet implementation at scale remains limited due to the absence of interoperable health IT solutions that integrate results into prescribi...
Finasteride, pharmacogenomics, and suicide risk: a public health concern [0.03%]
非那司提、药理基因组学与自杀风险——一个公共卫生问题
Carlos Perezcano,Mariana Pérez-Coria,Francisco Javier Borrayo-López
Carlos Perezcano
Cost-effectiveness of genome-guided statin treatment for hypercholesterolemia [0.03%]
基于基因组的他汀类药物治疗高胆固醇血症的成本效益分析
Margarita-Ioanna Koufaki,Korina Tzerefou,Achilleas Tyrovolas et al.
Margarita-Ioanna Koufaki et al.
Cardiovascular disease and hypercholesterolemia present significant global health and economic burdens. While statins are the standard treatment, individual variability and toxicities necessitate personalized approaches. This narrative revi...
Cost-effectiveness analysis of encorafenib in untreated BRAF V600E-mutant metastatic colorectal cancer in China [0.03%]
用于治疗BRAF V600E突变型转移性结直肠癌的恩考芬尼在中国的 cost-effectiveness分析
Shaohong Luo,Yijun Cai,Xiangzhen Wang et al.
Shaohong Luo et al.
This study assessed the cost-effectiveness of encorafenib plus cetuximab (EC) and EC combined with mFOLFOX6 versus standard of care (SOC) as first-line treatment for BRAF V600E-mutant metastatic colorectal cancer from a Chinese healthcare p...